SWE
Order GAD for preclinical research
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Press Releases
Skip Navigation Links
Home
»
Investors
»
Press Releases
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
Press Releases
Data pager
Data pager
1
2
Show:
PageSizeComboBox
select
10
20
50
100
150
2 pages
6-26-2019
Quarterly Report III 18/19
6-18-2019
Diamyd Medical’s intralymphatic diabetes therapy attracts increased interest
6-10-2019
Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue
6-4-2019
New interim report at 30 months and after extra injection supports long-term effect of intralymphatic Diamyd
®
5-29-2019
The Swedish Medical Products Agency approves new treatment arm with Remygen
®
and Alprazolam in Phase I/II trial ReGenerate-1
5-7-2019
Fully recruited European Phase IIb trial with the diabetes vaccine Diamyd
®
4-16-2019
Results from the EDCR IIa trial where Diamyd
®
is given subcutaneously
4-11-2019
Immunological findings supporting intralymphatic treatment with Diamyd
®
to be presented today at a diabetes meeting in Stockholm
3-27-2019
Quarterly Report II 18/19
3-26-2019
Diamyd Medical announces strategic activities for 2019 and 2020
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email